RNA Extraction from Blood: Protocols for Total RNA from Whole Blood

Total RNA extraction from whole blood is a foundational technique in molecular biology that enables gene expression analysis, biomarker discovery, and pathogen detection. The method involves lysing blood cells, stabilizing RNA, and purifying total RNA while removing abundant globin mRNA that can mask lower-abundance transcripts. This approach is essential when working with blood samples for transcriptomic studies, RT-qPCR, or RNA sequencing, particularly when the goal is to capture the full cellular transcriptome rather than cell-free RNA from plasma. The choice of protocol depends on sample volume, desired RNA yield, downstream application, and whether globin depletion is required.

At a Glance

Scientific Principle

Whole blood contains a complex mixture of cellular components: erythrocytes (red blood cells), leukocytes (white blood cells), platelets, and cell-free nucleic acids. Total RNA extraction from whole blood targets the cellular RNA fraction, primarily from leukocytes, which contain the nuclear and cytoplasmic RNA populations relevant for gene expression studies.

The extraction process follows three fundamental steps: cell lysis, phase separation or binding, and purification. In organic extraction methods (e.g., TRIzol), blood cells are lysed in a monophasic solution of phenol and guanidine isothiocyanate. Chloroform addition creates an aqueous phase containing RNA, an interphase containing DNA, and an organic phase containing proteins and lipids. RNA is then precipitated from the aqueous phase with isopropanol.

In column-based methods, blood is first subjected to red blood cell (RBC) lysis to remove hemoglobin and other erythrocyte components that can interfere with RNA binding. The remaining leukocytes are then lysed in a guanidine-based buffer that inactivates RNases and provides optimal conditions for RNA binding to silica membranes. After washing steps to remove contaminants, RNA is eluted in nuclease-free water or low-ionic-strength buffer.

A critical consideration unique to blood RNA extraction is the predominance of globin mRNA (alpha- and beta-globin transcripts), which can constitute 50–70% of total mRNA in whole blood samples. This abundance can mask detection of lower-expression transcripts and reduce sequencing efficiency. Many protocols therefore include a globin mRNA depletion step, either through selective hybridization with complementary oligonucleotides or through probe-based capture systems.

Materials and Instrumentation Choices

Blood Collection Tubes

The choice of blood collection tube significantly affects RNA yield and quality. EDTA tubes (purple top) are most common for RNA extraction because EDTA chelates calcium and magnesium, inhibiting nucleases and preventing coagulation. Citrate tubes (blue top) are also acceptable but may require protocol adjustments. PAXgene Blood RNA Tubes contain a proprietary RNA-stabilizing solution that immediately lyses cells and stabilizes RNA, allowing storage at room temperature for up to 5 days or at -20°C for longer periods. For fresh blood, processing within 30 minutes is recommended to minimize RNA degradation.

RBC Lysis Buffers

Commercial RBC lysis buffers typically contain ammonium chloride (NH₄Cl) and potassium bicarbonate (KHCO₃) in a hypotonic solution that selectively lyses erythrocytes while leaving leukocytes intact. Alternatively, some protocols use a brief hypotonic shock with sterile water. The choice depends on downstream compatibility: ammonium chloride-based buffers are gentler on leukocytes and produce higher RNA yields, while water lysis is faster but may cause some leukocyte loss.

RNA Stabilization and Lysis Reagents

TRIzol (or TRI Reagent) is a monophasic solution of phenol and guanidine isothiocyanate that simultaneously lyses cells and inactivates RNases. It is effective for blood samples but requires careful phase separation and can be hazardous due to phenol content. Guanidine-based lysis buffers (e.g., those in Qiagen RNeasy kits) provide safer handling and are compatible with column purification. For automated platforms, manufacturer-specific lysis buffers are required.

Purification Systems

Silica-column purification (e.g., Qiagen RNeasy, Zymo Quick-RNA) offers high-purity RNA suitable for most downstream applications. Columns bind RNA under high-salt conditions and release it in low-salt buffer. Magnetic bead-based purification (e.g., Agencourt RNAClean XP) is scalable and compatible with automation but may require optimization for blood samples. Automated platforms such as QIAcube, EZ1 Advanced, and Maxwell RSC provide standardized extraction with reduced hands-on time. A comparative evaluation of these platforms for viral RNA recovery from whole blood showed that extraction efficiency varies substantially by platform and specimen type, with the Maxwell RSC achieving the highest RNA recovery in whole blood for certain targets [1].

Globin Depletion Kits

Several commercial kits are available for globin mRNA reduction. GLOBINclear (Thermo Fisher) uses biotinylated oligonucleotides complementary to human alpha- and beta-globin mRNA, followed by streptavidin magnetic bead capture. Ribo-Zero Globin (Illumina) uses probe-based rRNA and globin mRNA depletion. PAXgene Blood RNA Kit includes an optional globin reduction step. For porcine samples, species-specific globin blockers have been used successfully to minimize the impact of globin transcripts in 3' mRNA sequencing [3].

Controls

Proper controls are essential for reliable RNA extraction and downstream analysis.

Positive control: A known RNA sample (e.g., commercially available human reference RNA) processed in parallel to verify extraction efficiency. This control should yield expected RNA concentration and integrity values.

Negative control: Nuclease-free water processed through the entire extraction protocol to detect reagent contamination. This control should yield no detectable RNA.

Extraction control: A blood sample with known RNA yield and quality (e.g., from a healthy donor) processed alongside experimental samples to monitor day-to-day variation.

Globin depletion control: For protocols including globin reduction, a paired sample processed without depletion allows assessment of depletion efficiency. RT-qPCR for globin mRNA (HBA1, HBB) and a housekeeping gene (e.g., GAPDH) can quantify depletion.

Carryover control: For automated platforms, include an empty cartridge or well to detect cross-contamination between samples.

Conceptual Workflow

Step 1: Sample Preparation and RBC Lysis

If using fresh blood collected in EDTA tubes, process within 30 minutes. For PAXgene tubes, follow manufacturer instructions for stabilization and storage. Begin by lysing erythrocytes: add 3 volumes of RBC lysis buffer to 1 volume of whole blood, mix gently, and incubate at room temperature for 10–15 minutes with occasional inversion. Centrifuge at 300–500 × g for 5 minutes to pellet leukocytes. Remove supernatant carefully, as the pellet is loose. Repeat lysis if the pellet appears red (indicating incomplete RBC removal).

Step 2: Leukocyte Lysis and RNA Stabilization

Resuspend the leukocyte pellet in lysis buffer containing guanidine isothiocyanate and β-mercaptoethanol (or DTT) to inactivate RNases. Vortex or pipette to ensure complete lysis. For TRIzol-based methods, add 1 mL TRIzol per 5–10 × 10⁶ cells and homogenize by pipetting.

Step 3: Phase Separation (Organic Extraction) or Column Binding

For organic extraction: Add 0.2 mL chloroform per 1 mL TRIzol, shake vigorously for 15 seconds, and incubate at room temperature for 2–3 minutes. Centrifuge at 12,000 × g for 15 minutes at 4°C. Transfer the upper aqueous phase to a new tube, being careful not to disturb the interphase. Add 0.5 mL isopropanol, mix, and incubate at room temperature for 10 minutes. Centrifuge at 12,000 × g for 10 minutes at 4°C. Wash the RNA pellet with 75% ethanol, air-dry, and resuspend in RNase-free water.

For column purification: Add an equal volume of 70% ethanol to the lysate and mix by pipetting. Transfer to a silica column, centrifuge at 8,000–10,000 × g for 15–30 seconds, and discard flow-through. Wash with provided buffers (typically RW1 and RPE), then elute in 30–50 µL RNase-free water.

Step 4: Globin mRNA Depletion (Optional)

If using a globin depletion kit, follow manufacturer instructions. Typically, this involves adding biotinylated globin-specific probes to the RNA sample, incubating at 70°C for 5 minutes, then adding streptavidin magnetic beads. After incubation at room temperature for 15 minutes, place on a magnetic stand and transfer the supernatant (depleted RNA) to a new tube. The globin-bound beads are discarded.

Step 5: RNA Quantification and Quality Assessment

Measure RNA concentration using spectrophotometry (NanoDrop or similar). Pure RNA has an A₂₆₀/A₂₈₀ ratio of 1.8–2.1 and an A₂₆₀/A₂₃₀ ratio of 2.0–2.2. Assess integrity using capillary electrophoresis (e.g., Agilent Bioanalyzer) or denaturing agarose gel electrophoresis. The RNA Integrity Number (RIN) should be ≥7 for most downstream applications, though some protocols accept RIN ≥5 for certain RNA-seq methods.

Quality Checks

Spectrophotometric Assessment

• A₂₆₀/A₂₈₀ ratio: Values below 1.8 indicate protein or phenol contamination. Values above 2.1 may indicate RNA degradation or residual guanidine.
• A₂₆₀/A₂₃₀ ratio: Values below 1.8 suggest carbohydrate or guanidine contamination.
• Concentration: Should be consistent with expected yield based on white blood cell count. Normal adult blood contains 4,000–11,000 leukocytes/µL, yielding approximately 3–10 µg total RNA per mL whole blood.

Integrity Assessment

• RIN value: A RIN of 7–10 indicates intact RNA suitable for most applications. RIN 5–7 may be acceptable for RT-qPCR but not for RNA-seq. RIN <5 suggests significant degradation.
• Gel electrophoresis: Intact RNA shows two distinct ribosomal RNA bands (28S and 18S in mammals) with a 28S:18S ratio of approximately 2:1. Smearing indicates degradation.
• Globin depletion efficiency: For globin-reduced samples, RT-qPCR for globin mRNA should show at least 80% reduction compared to non-depleted controls.

Yield Considerations

Yield varies with leukocyte count, extraction method, and sample handling. Automated platforms can show substantial differences in RNA recovery from whole blood, with some systems performing better for specific sample types [1]. For lipid-rich samples, organic extraction with TRIzol and chloroform has been shown to yield higher RNA amounts and purity compared to column-based methods [2], though this observation comes from adipose tissue rather than blood.

Result Interpretation

Normal Results

• Concentration: 50–200 ng/µL (from 1 mL whole blood, eluted in 30–50 µL)
• A₂₆₀/A₂₈₀: 1.9–2.1
• A₂₆₀/A₂₃₀: 2.0–2.2
• RIN: ≥7
• 28S:18S ratio: 1.5–2.5

Abnormal Results and Their Meaning

Troubleshooting

Limitations

Sample-Related Limitations

• Hemolyzed samples: Hemolysis releases hemoglobin and other erythrocyte contents that can interfere with RNA binding and spectrophotometric measurements. If hemolysis is visible, consider using a specialized protocol for hemolyzed blood or increasing wash steps.
• Low leukocyte count: Patients with leukopenia (e.g., chemotherapy patients) yield less RNA. For such samples, consider using larger blood volumes (up to 5 mL) or concentrating the RNA during elution.
• Stabilization requirements: RNA is labile, and blood must be processed quickly or stabilized. PAXgene tubes are effective but expensive. EDTA tubes require processing within 30 minutes for optimal RNA quality.

Method-Specific Limitations

• Organic extraction: Phenol and chloroform are hazardous and require proper fume hood use. Residual phenol can inhibit downstream enzymatic reactions. The method is more labor-intensive than column-based approaches.
• Column purification: Columns can clog with viscous samples or high cell numbers. Some RNA species (e.g., small RNAs) may be lost during washing steps. Binding capacity is limited (typically 100 µg per column).
• Automated platforms: Require specific cartridges and reagents that may be costly. Performance varies by platform and sample type, as demonstrated by comparative evaluations showing that no single system is optimal for all matrices [1].
• Globin depletion: Adds cost and processing time. Some depletion methods may also remove non-globin transcripts, potentially biasing downstream analysis. Depletion efficiency varies with RNA quality and input amount.

Application-Specific Limitations

• RNA-seq: Requires high-quality RNA (RIN ≥7) for most library preparation methods. Globin depletion is strongly recommended for whole blood RNA-seq to improve detection of low-abundance transcripts.
• RT-qPCR: More tolerant of partially degraded RNA, but globin depletion may still be beneficial for detecting low-expression targets.
• Microarray analysis: Globin depletion is often recommended to reduce background and improve signal-to-noise ratio.

Documentation

Proper documentation ensures reproducibility and compliance with laboratory standards. For each RNA extraction, record the following:

Pre-Extraction Information

• Sample identifier and collection date/time
• Blood collection tube type (EDTA, citrate, PAXgene)
• Storage conditions before extraction (temperature, duration)
• Visual assessment of sample (hemolysis, clotting, volume)
• Leukocyte count if available

Extraction Parameters

• Extraction method and kit (including lot number)
• Volume of blood processed
• RBC lysis buffer type and incubation time
• Lysis buffer composition and volume
• Centrifugation speeds and times
• Elution volume
• Globin depletion method (if used)
• Any deviations from standard protocol

Quality Control Data

• RNA concentration (ng/µL)
• A₂₆₀/A₂₈₀ and A₂₆₀/A₂₃₀ ratios
• RIN value or gel image
• Globin depletion efficiency (if assessed)
• Yield calculation (total µg RNA)

Post-Extraction Information

• Storage conditions (temperature, aliquot size)
• Downstream application planned
• Date and operator initials

Biosafety

Risk Assessment

Human blood is classified as BSL-2 material in many jurisdictions due to the potential presence of bloodborne pathogens such as hepatitis B virus (HBV), hepatitis C virus (HCV), and human immunodeficiency virus (HIV). However, for educational and teaching laboratory contexts where samples are from known low-risk donors or are commercially sourced and tested, BSL-1 practices with universal precautions are often appropriate. Always consult institutional biosafety guidelines and the CDC/NIH BMBL for specific requirements [5].

Universal Precautions

• Treat all human blood as potentially infectious.
• Wear appropriate personal protective equipment (PPE): lab coat, gloves, and eye protection.
• Perform all steps involving blood in a biosafety cabinet (BSC) if splashing or aerosol generation is possible.
• Use leak-proof tubes for blood collection and processing.
• Decontaminate work surfaces with 10% bleach or appropriate disinfectant after each use.

Chemical Hazards

• Phenol and chloroform: Use in a chemical fume hood. Phenol is corrosive and can cause severe burns. Chloroform is a suspected carcinogen. Collect waste in designated containers.
• Guanidine isothiocyanate: Irritant; avoid skin contact. Incompatible with bleach (can produce toxic gases).
• β-mercaptoethanol: Toxic; use in fume hood. Strong odor indicates inadequate ventilation.

Waste Disposal

• Liquid blood waste: Autoclave or treat with bleach (10% final concentration for 30 minutes) before disposal.
• Solid waste (tubes, tips, columns): Dispose in biohazard waste containers for incineration or autoclaving.
• Organic solvent waste: Collect separately for hazardous waste disposal.

Recombinant DNA Considerations

If extracted RNA will be used for downstream applications involving recombinant or synthetic nucleic acids (e.g., cloning, in vitro transcription), follow NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules [6]. This may require institutional biosafety committee (IBC) approval and appropriate containment levels.

Frequently Asked Questions

1. Can I use heparin tubes for RNA extraction from blood?

Heparin is a potent inhibitor of reverse transcriptase and Taq polymerase, making it unsuitable for RNA extraction intended for RT-qPCR or RNA-seq. Heparin is difficult to remove during RNA purification and can persist through column cleanup. Always use EDTA or citrate tubes for blood RNA extraction. If heparin tubes are the only option, consider using a heparin removal step (e.g., heparinase treatment) before downstream applications.

2. How long can I store whole blood before RNA extraction?

For EDTA or citrate tubes, process within 30 minutes for optimal RNA quality. Storage at 4°C for up to 2 hours may be acceptable but will result in some RNA degradation. PAXgene tubes stabilize RNA for up to 5 days at room temperature, 14 days at 4°C, or longer at -20°C. Never freeze whole blood in EDTA tubes, as freeze-thawing lyses cells and releases RNases.

3. Is globin depletion always necessary for blood RNA-seq?

Globin depletion is strongly recommended for whole blood RNA-seq because globin mRNA can constitute 50–70% of total mRNA, reducing sequencing depth for other transcripts. However, if the research question focuses specifically on globin expression or if using a 3' mRNA-seq approach that may be less affected by globin abundance, depletion may be optional. For RT-qPCR targeting high-expression genes, depletion is usually unnecessary.

4. Why is my RNA yield lower than expected from whole blood?

Several factors can reduce yield: incomplete RBC lysis (leaving leukocytes trapped in erythrocyte debris), leukocyte loss during washing steps (centrifugation at too high speed), RNA degradation during processing, or column overloading. Check the pellet color after RBC lysis—a white pellet indicates complete lysis, while a red pellet suggests residual erythrocytes. Also verify that the blood sample had a normal leukocyte count; leukopenic patients will yield less RNA.

References and Further Reading

1. Treggiari D, Castilletti C, Nicolini L, Mazzi C, Perandin F, Formenti F. Comparative Evaluation of Automated Nucleic Acid Extraction Systems for DNA and RNA Viral Target. 2026. PubMed ID: 41599055. https://pubmed.ncbi.nlm.nih.gov/41599055/

2. De Azevedo N, Lozano A, Parsons RE, Martin TC. Optimized Protocols to Extract Total Transcripts and Proteins from Lipid-Rich Tissues. 2026. PubMed ID: 42042616. https://pubmed.ncbi.nlm.nih.gov/42042616/

3. Payros G, Jason K, Gress L, Gusmini M, Liaubet L, Lippi Y. Transcriptomic data of piglet blood compartments with 3' mRNA sequencing. 2026. PubMed ID: 41889667. https://pubmed.ncbi.nlm.nih.gov/41889667/

4. Kegler U, Buhmann A, Friedl HP, Hofner M, Noehammer C. Comparison of Methods for the Isolation of Salivary Extracellular Vesicles. 2026. PubMed ID: 42278431. https://pubmed.ncbi.nlm.nih.gov/42278431/

5. CDC and NIH. Biosafety in Microbiological and Biomedical Laboratories (BMBL), 6th Edition. U.S. Department of Health and Human Services, 2020. https://www.cdc.gov/labs/bmbl/index.html

6. National Institutes of Health. NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules. https://osp.od.nih.gov/policies/biosafety-and-biosecurity-policy/nih-guidelines-for-research-involving-recombinant-or-synthetic-nucleic-acid-molecules/

7. National Center for Biotechnology Information. NCBI Bookshelf: Molecular Biology and Laboratory Methods. https://www.ncbi.nlm.nih.gov/books/

Related Articles

• RNA Extraction from Bacteria: Protocols for Total RNA Isolation
• RNA Extraction from FFPE Tissues: Challenges and Protocols
• Genomic DNA Extraction from Blood: Protocols and Quality Assessment
• RNA Extraction from Plant Tissues: Methods and Troubleshooting
• DNA Extraction from Soil: Protocols for Environmental Samples
• mRNA Purification from Total RNA: Poly(A) Selection Methods